title: Retardation of the development of hypertension in DOCA salt rats by taurine supplement.
abstract: To study the antihypertensive effect of orally administered taurine in DOCA salt hypertension, urinary excretion of catecholamines, electrolytes, and arg-vasopressin was measured over four weeks in 20 taurine treated DOCA rats (group 1), 20 taurine untreated DOCA rats (group 2), and seven taurine untreated sham operated rats (group 3). Additional experiments were performed to determine whether or not the pressor and sympathetic responses to hypothalamic stimulation were altered after taurine treatment in DOCA rats. Systolic blood pressure decreased significantly in group 1 after the first week compared with that in group 2, and the differences became progressively more evident thereafter. At the fifth week the mean blood pressure was significantly lower in group 1 than in group 2, as was the heart rate. Although urinary excretion of adrenaline decreased significantly in group 1 at the first and fourth weeks, the difference in urinary excretion of noradrenaline between groups 1 and 2 was not significant. Urinary excretion of adrenaline and noradrenaline in group 3 was significantly lower than that in both hypertensive groups (groups 1 and 2). Urinary sodium excretion increased significantly in group 1 at the first and second week compared with group 2. With graded electrical stimulation of the ventromedial hypothalamus, resulting pressor and sympathetic responses were significantly smaller in group 1 than in group 2. These results suggest that the hypotensive effects of orally administered taurine in DOCA hypertensive rats are caused by suppression of the peripheral sympathetic nervous activity and by the resulting natriuresis.
authors.affiliation: 2nd Department of Medicine, Kyoto Prefectural University of Medicine, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Inoue
authors.forename: H
authors.initials: H
authors.lastname: Takahashi
authors.forename: L C
authors.initials: LC
authors.lastname: Lee
authors.forename: S
authors.initials: S
authors.lastname: Sasaki
authors.forename: Y
authors.initials: Y
authors.lastname: Kohno
authors.forename: K
authors.initials: K
authors.lastname: Takeda
authors.forename: M
authors.initials: M
authors.lastname: Yoshimura
authors.forename: M
authors.initials: M
authors.lastname: Nakagawa
mesh_terms: D000818:Animals; D001127:Arginine Vasopressin / Q000652:urine; D001794:Blood Pressure / Q000187:drug effects; D003864:Depression, Chemical; D003900:Desoxycorticosterone; D004837:Epinephrine / Q000652:urine; D006973:Hypertension / Q000139:chemically induced / Q000188:drug therapy* / Q000652:urine; D008297:Male; D009638:Norepinephrine / Q000494:pharmacology / Q000652:urine; D011188:Potassium / Q000652:urine; D051381:Rats; D011919:Rats, Inbred Strains; D012964:Sodium / Q000652:urine; D013564:Sympathetic Nervous System / Q000187:drug effects; D013654:Taurine / Q000627:therapeutic use*
chemical_list: D001127:Arginine Vasopressin; D013654:Taurine; D003900:Desoxycorticosterone; D012964:Sodium; D011188:Potassium; D009638:Norepinephrine; D004837:Epinephrine